Opendata, web and dolomites

BoVLP-BVD

Development of Tagged (DIVA), Virus-Like-Particle polyantigenic Vaccine against Bovine Viral Diarrhea virus (BVDc)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BoVLP-BVD project word cloud

Explore the words cloud of the BoVLP-BVD project. It provides you a very rough idea of what is the project "BoVLP-BVD" about.

prevent    diseases    public    vaccine    antibiotics    environmental    oacute    animals    food    confirming    basic    modified    precisely    social    bvd    aquil    antigenic    point    calendar    prospective    experimental    viral    incidence    million    herds    productivity    agro    market    disease    virus    feasibility    bodies    vaccination    tagged    endemic    profile    approximately    eradication    programs    manufacturing    hut    fight    herd    countries    50    intends    hundreds    live    decide    had    infected    vaccinated    systematic    investing    becomes    livestock    recombinant    economic    differentiate    patented    vaccines    suboptimal    start    formulation    cattle    commercial    fulfil    infectious    tool    exposed    confirm    wishes    exploring    persistent    worldwide    plan    bovine    reproduction    euros    poly    mandatory    industry    agent    90    business    of    systematically    pressure    context    animal    prior    diarrhea    lifetime    bvdv    killed    particle    reduce    regulatory    infection   

Project "BoVLP-BVD" data sheet

The following table provides information about the project.

Coordinator
AQUILON CYL SOCIEDAD LIMITADA 

Organization address
address: LUGAR FACULTAD DE VETERINARIA S/N CAMPUS VEGAZANA
city: LEON
postcode: 24000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.aquiloncyl.com/proyectos-i-d/vacuna-contra-la-diarrea-virica-bovina
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy)
2. H2020-EU.3.2.1. (Sustainable agriculture and forestry)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2017-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AQUILON CYL SOCIEDAD LIMITADA ES (LEON) coordinator 50˙000.00

Map

 Project objective

In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime.Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals. Modified, live and killed vaccines have been available for more than 50 years, yet the incidence of BVDV-induced disease remains significant, confirming a need for improved vaccines. Aquilón intends to develop a new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. The vaccine will be poly-antigenic, non-live, tagged so that can differentiate vaccinated from infected animals, and cost-effective from the manufacturing side. Prior to start the experimental phase of the project, Aquilón wishes to confirm its commercial feasibility, defining precisely the Target Product Profile and exploring systematically its market potential and prospective cost/calendar of development to fulfil regulatory requirements. These studies are mandatory for the formulation of a business plan which will be the basic tool to decide investing in the future development of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BOVLP-BVD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BOVLP-BVD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.2.4.;H2020-EU.3.2.1.;H2020-EU.2.3.1.;H2020-EU.3.2.2.)

Stoock (2018)

An Innovative Integrated Field Sensor system providing a precise farming tool to reduce productioncosts and water wastage.

Read More  

INSYLO (2018)

Disruptive IoT solution for optimising the animal feed supply chain

Read More  

INDI (2018)

INDI, world’s first 100% dairy free, soy-free infant-formula.

Read More